An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases
CA 2448086 A1 · Owner: Pfizer Limited · Inventors: Armstrong, Roisin A.; Yeadon, Michael
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a combination of a selective adenosine A2a receptor agonist and an anticholinergic agent for simultaneous sequential or , separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease with the proviso that the , anticholinergic agent is not a tiotropium salt.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 24, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 24, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 24, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.